Drugs / JNJ-54416076
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02951845 | Nov 2016 → Feb 2017 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02670395 | Apr → Sep 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-54416076 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02951845 ↗ |
| Route | Oral | “JNJ-54416076 suspension will be administered orally.” NCT02670395 ↗ |